Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

A0200000

Acetylsalicylic acid

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
2-(CH3CO2)C6H4CO2H
Numéro CAS:
50-78-2
Poids moléculaire :
180.16
Numéro Beilstein :
779271
Numéro MDL:
MFCD00002430
Code UNSPSC :
41116107
ID de substance PubChem :
329770581
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

aspirin

Fabricant/nom de marque

EDQM

Pf

134-136 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

Clé InChI

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1044006

Aspirin, United States Pharmacopeia (USP) Reference Standard

Y0001460

Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard

1609807

Salsalate, United States Pharmacopeia (USP) Reference Standard

1696200

Trisalicylic acid, United States Pharmacopeia (USP) Reference Standard

BP617

Aspirin, British Pharmacopoeia (BP) Reference Standard

PHR1940

Aspirin Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1941

Aspirin Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1942

Aspirin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

482.0 °F

Point d'éclair (°C)

250 °C

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

Salicylic acid United States Pharmacopeia (USP) Reference Standard

USP

1609002

Salicylic acid

Salicylic acid British Pharmacopoeia (BP) Reference Standard

BP775

Salicylic acid

Aspirin Impurity E Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1941

Aspirin Impurity E

Salicylic acid impurity B European Pharmacopoeia (EP) Reference Standard

Y0000405

Salicylic acid impurity B

Mefenamic acid European Pharmacopoeia (EP) Reference Standard

M0252600

Mefenamic acid

Salicylic acid BioXtra, ≥99.0%

Sigma-Aldrich

S5922

Salicylic acid

Salicylic acid certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Supelco

52341

Salicylic acid

Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique